TMBIM4 and Parkinson disease: S1R agonism through PRE-084, either alone or in combination with nicotinic receptor agonists, has shown efficacy in preserving dopaminergic neurons, which are preferentially impacted in PD, as well as providing neuroprotection from MPTP-induced neuronal damage [165,166,167].